|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ELISA was used for detection of the level of interleukin (IL)-1β, IL-18, tumor necrosis factor (TNF)-α, IL-6, myeloperoxidase (MPO) and tumor growth factor (TGF)-β1.
|
31301646 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, reactive oxygen species (ROS) and myeloperoxidase generated in inflammatory sites or the tumor microenvironment trigger bioluminescence resonance energy transfer and the production of singlet oxygen (<sup>1</sup>O<sub>2</sub>) from the nanoparticle, enabling in vivo imaging and cancer therapy, respectively.
|
30662940 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Treatment with the combination elicited a robust systemic and tumor-specific immune response with (a) increased percentages of systemic and tumor infiltrated CD45+CD11b+ cells, (b) increased levels of myeloperoxidase (MPO), (c) increased antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), (d) decreased percentage of immune regulatory cells (CD8+CD69+ cells), and (e) reduced circulating levels of immunosuppressive tMUC1.
|
31114758 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PD-L1 tumor expression was assessed using immunohistochemistry with two antibodies (clones 5H1 and E1L3N), and tumor immune-cell infiltration with CD3, CD4, CD8, CD20, CD163, and MPO.
|
29194117 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Control and AEST-treated mice were observed for different oxidative stress parameters, nitric oxide (NO) release, and myeloperoxidase (MPO) release, and they were evaluated for alterations in tumor suppressor and DNA repair responses in the liver and spleen.
|
29283338 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor-bearing animals exhibited increased levels of plasma DNA and myeloperoxidase in addition to significantly increased numbers of circulating neutrophils.
|
28743887 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that MPO and EPO stimulation increased mammary tumour growth and enhanced lung metastases, effects that were associated with reduced tumour necrosis, increased collagen deposition and neo-vascularisation within the primary tumour.
|
28260049 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased levels of myeloperoxidase, a neutrophil marker and those of vascular endothelial growth factor were observed in tumors with G-CSF supplementation.
|
25976379 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MPO has been either directly or indirectly linked to neoplasia, which is a well-established risk factor for many types of cancer.
|
23991124 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The first group comprised myelomonocytic cell tumors (n=18), exhibiting a proliferation of granulocytic or monocytic blast cells, which were CD68 and/or MPO positive but negative for dendritic cell markers.
|
22895265 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leukemic mice typically had enlarged spleens, invasion of parenchymal organs with malignant cells, and tumors with myeloid markers such as myeloperoxidase, Mac1, and Gr1.
|
17804713 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor differentiation was also not found to be associated with the MPO genotype.
|
16829688 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The neutrophil content of tumors (as measured by myeloperoxidase) was directly proportional to the level of IL-8 expressed at the time tumors were excised.
|
11181444 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, 75-100% of informative cases exhibited LOH at the loci p53, D17S1322 (intragenic to the tumor suppressor gene BRCA1), D17S1327 and MPO.
|
9692553 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that D17S250 was deleted in 50% (7 of 14), THRA1 in 79% (11 of 14), D17S579 in 59% (11 of 19), NME1 in 29% (5 of 17), MPO in 36% (4 of 11), and GH in 25% (4 of 16) in the tumor set examined.
|
1568230 |
1992 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The level of myeloperoxidase (MPO) mRNA is reduced significantly after HL-60 induced differentiation with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA).
|
1849601 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Regulation of myeloperoxidase gene expression by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate in human leukemia HL-60 cells.
|
3023307 |
1986 |